CRISPR Therapeutics AG [CRSP] stock is trading at $44.20, up 6.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRSP shares have gain 15.22% over the last week, with a monthly amount glided 7.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on August 06, 2024, when Needham reiterated its Buy rating and also revised its price target to $84 from $88. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 02, 2024, and set its price target to $90. Wolfe Research started tracking the stock assigning a Peer Perform rating. TD Cowen downgraded its rating to a Underperform but $30 remained the price target by the analyst firm on December 11, 2023. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 17, 2023. In a note dated September 27, 2023, Mizuho initiated an Buy rating and provided a target price of $82 on this stock.
CRISPR Therapeutics AG [CRSP] stock has fluctuated between $36.52 and $91.10 over the past year. Currently, Wall Street analysts expect the stock to reach $77.5 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $44.20 at the most recent close of the market. An investor can expect a potential return of 75.34% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -1.65%, Pretax Profit Margin comes in at -1.17%, and Net Profit Margin reading is -1.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.12 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.67 points at the first support level, and at 39.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.25, and for the 2nd resistance point, it is at 48.30.
Ratios To Look Out For
For context, CRISPR Therapeutics AG’s Current Ratio is 21.64. On the other hand, the Quick Ratio is 21.64, and the Cash Ratio is 2.51. Considering the valuation of this stock, the price to sales ratio is 18.60, the price to book ratio is 1.94.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Dec 02 ’24 when 15000.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Nov 11 ’24 to sell 30000.0 shares. Meanwhile, General Counsel and Secretary KASINGER JAMES R. sold 1089.0 shares on Oct 14 ’24.
